A serum proteomics‐based predictive model for steroid‐resistant immune checkpoint inhibitor associated myocarditis
Clinical and Translational Medicine · 2026
DOI: 10.1002/ctm2.70843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Yerui Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. Hauptthemen laut MEDLINE: Myocarditis, Immune Checkpoint Inhibitors, Proteomics. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, Shanghai Shenkang Hospital Development Center municipal hospital diagnosis and treatment technology project.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitor–associated myocarditis (ICIAM) is one of the immune–related adverse events (irAEs) with low incidence but extremely high mortality. High–dose glucocorticoid pulse therapy remains the recommended initial treatment for patients with ICIAM. However, an inadequate response to corticosteroid therapy is observed in some patients, who are subsequently classified as having steroid‐resistant immune checkpoint inhibitor‐associated myocarditis (srICIAM). Early combination of second‐line immunosuppression may represent an effective therapeutic strategy. However, Biomarkers capable of identifying such patients before treatment are currently lacking. We therefore sought to characterize circulating inflammatory proteins associated with corticosteroid responsiveness and to derive a preliminary serum‐based prediction model for steroid‐resistant ICIAM (srICIAM).
Methods
Serum specimens obtained from patients with ICIAM at baseline and after methylprednisolone treatment were analyzed to quantify circulating immune‐related proteins using an antibody‐based proteomic assay. We developed a preliminary model for the early identification of patients at risk of srICIAM using proteins selected by three complementary machine–learning algorithms and evaluated its discriminatory performance in an internal hold‐out cohort.
Results
Pretreatment serum samples from 47 patients with ICIAM were used to establish a protein–based prediction model, with 33 patients assigned to model development and 14 to internal validation. Patients with a high srICIAM predictive score (≥.5625) based on CXCL9, TRANCE and MMP1 were more likely to show an inadequate early response to corticosteroid therapy and may warrant closer clinical monitoring and further evaluation. The analysis also revealed that several serum immune proteins decreased in patients with ICIAM after methylprednisolone therapy. Serum CXCL9 levels were positively correlated with lactate dehydrogenase (LDH) and cardiac troponin T (cTnT).
Conclusion
Serum immune proteins were dynamically altered in patients with ICIAM after methylprednisolone therapy. The preliminary score may enable earlier recognition of patients at risk of an inadequate corticosteroid response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
- State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
- Shanghai Institute of Medical Imaging, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Cardiovascular Medicine, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
- Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Jian Zhang, Yihui Shen, Jianan Pan, Leilei Cheng
Förderung
- National Natural Science Foundation of China
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Shanghai Shenkang Hospital Development Center municipal hospital diagnosis and treatment technology project
- Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- Shanghai Shenkang Hospital Development Center
Zitieren
APA
Zhang, Y., Li, Y., Zhang, J., He, X., Shen, Y., Xu, Y., Zhang, H., Pan, J., Wang, X., Zhang, S., Wang, Y., & Cheng, L. (2026). A serum proteomics‐based predictive model for steroid‐resistant immune checkpoint inhibitor associated myocarditis. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70843
Vancouver
Zhang Y, Li Y, Zhang J, He X, Shen Y, Xu Y, et al. A serum proteomics‐based predictive model for steroid‐resistant immune checkpoint inhibitor associated myocarditis. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70843
BibTeX
@article{Zhang2026,
author = {Zhang, Yerui and Li, Yihan and Zhang, Jian and He, Xiaozhen and Shen, Yihui and Xu, Yuchen and Zhang, Hui and Pan, Jianan and Wang, Xuejun and Zhang, Shilong and Wang, Yan and Cheng, Leilei},
title = {A serum proteomics‐based predictive model for steroid‐resistant immune checkpoint inhibitor associated myocarditis},
journal = {Clinical and Translational Medicine},
year = {2026},
doi = {10.1002/ctm2.70843}
}
EUVIMED